Therapeutic Solutions plans to start breast cancer trial using FloraStilbene

Mar. 06, 2023 10:53 AM ETTherapeutic Solutions International, Inc. (TSOI)By: Ravikash, SA News Editor

Doctor doing research in lab during COVID-19

Morsa Images/DigitalVision via Getty Images

  • Therapeutic Solutions International (OTCPK:TSOI) said it plans to start a 10-patient proof-of-concept trial via Res Nova Bio subsidiary aimed at showing the ability of FloraStilbene to stimulate the immune system in patients with advanced breast cancer.
  • The company noted that it received a patent on using  pterostilbene and pterostilbene compositions for synergy with cancer immunotherapy.
  • TSOI noted the creation of a novel immune stimulatory adjuvant combining pterostilbene with RU-486 called FloraStilbene.
  • "FloraStilbene represents a non-toxic approach to overcoming breast cancer induced immune suppression, which acts as a significant barrier to efficacy of oncology immunotherapy," said Chief Medical Officer James Veltmeyer.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.